RELB and lung carcinoma: Increased β3, by interacting with galectin-3, thus activating KRAS, RELB, and NF-ΚB pathways, is involved in erlotinib and lapatinib resistance in lung cancer and linsitinib resistance in pancreatic cancer [5,28].